Spartalizumab
Product Specifications
UNSPSC Description
Spartalizumab (PDR001) is a humanized immunoglobulin 4 monoclonal antibody that binds PD-1 with subnanomolar activity and blocks interaction with PD-L1 and PD-L2. Spartalizumab can be used for the research of anaplastic thyroid carcinoma (ATC)[1].
Target Antigen
PD-1/PD-L1
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/spartalizumab.html
Purity
99.50
Solubility
H2O
Smiles
[Spartalizumab]
References & Citations
[1]Jaume Capdevila, et al. PD-1 Blockade in Anaplastic Thyroid Carcinoma. J Clin Oncol. 2020 Aug 10;38(23):2620-2627.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-P9972/Spartalizumab-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-P9972/Spartalizumab-SDS-MedChemExpress.pdf
Clinical Information
Phase 3
CAS Number
1935694-88-4
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
48599121 3 x 1.0μg DNA
TSPAN9 CRISPRa sgRNA lentivector (set of three targets)(Human)
Ask
View Details LS005289 100 µg
PI 3 Kinase Class 3 (PIK3C3) (NM_002647) Human Over-expression Lysate
Ask
View Details 